WHO ICTRP trial
Effects of aldosterone antagonism on microvascular function in obese individuals
NL-OMON45212 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON45212 |
|---|---|
| Public title | Effects of aldosterone antagonism on microvascular function in obese individuals |
| Scientific title | Effects of aldosterone antagonism on microvascular function in obese individuals - Aldosterone antagonism and microvascular function |
| Primary sponsor | Universiteit Maastricht |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | hypertension/high blood pressure; insulin resistance/decreased sensitivity for insulin;10018424;10057166;hypertension/high blood pressure; insulin resistance/decreased sensitivity for insulin |
| Interventions | 30 obese individuals will be randomized to treatment with the selective mineralocorticoid receptor antagonist Eplerenone, 50 mg once daily during 4 weeks. The remaining 30 obese individuals will be randomized to treatment with a matched… |
| Registration date | Nov 3, 2016 |
| Target size | 60 |
| Secondary IDs | NCT01887119;NL44235.068.13 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: